Antidote is a digital health company focused on accelerating and improving medical research. By combining proprietary technologies, data, and well-established business models, the company is transforming the way patients and researchers connect so that breakthroughs happen faster. Antidote was launched as TrialReach in 2010 and rebranded to Antidote in 2016. The company is based in the US and the UK.

England, UK

London, UK

Mile End, London, UK

Kingston Vale, London SW15, UK

Antidote.me

Series B

Healthcare

We seek talented teams intent on building businesses that can scale to create or transform an industry. If this describes you, then please get in touch

Octopus Ventures

Tell us about your professional DNA to get discovered by any company in our network with opportunities relevant to your career goals.

Leverage our network to build your career.

#### Welcome!

Thank you for joining Octopus Ventures Network!

To help us best support you in your search, please take a few minutes to tell us about what you are looking for in your next role. We’ll use this information to connect you to relevant opportunities in the Octopus Ventures network as they come up.

You can always update this information later.

Welcome to the Octopus Ventures talent network

As our companies grow, they look to us to help them find the best talent.

Signal that you'd be interested in working with a Octopus Ventures company to help us put the right opportunities at great companies on your radar. The choice to pursue a new career move is then up to you.

Your professional information is now visible to our team and companies in our network.
We will be in touch when we find a great opportunity for you at one of our companies.

Thanks for signing up

As our companies grow, they look to us to help them find the best talent.
Signal that you'd be interested in working with a Octopus Ventures company to help us put the right opportunities at great companies on your radar. The choice to pursue a new career move is then up to you.

Job opportunities in the Octopus Ventures portfolio